Nuvalent

Nuvalent is a biotechnology company dedicated to developing precisely targeted therapies for patients with cancer. The company focuses on creating small molecules that inhibit clinically proven kinase targets, addressing issues of resistance and selectivity in cancer treatments. Nuvalent boasts a robust pipeline, including parallel lead programs targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). Additionally, the company engages in multiple discovery-stage research programs. At the AACR Annual Meeting 2024, Nuvalent presented new preclinical data supporting the profiles of its HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib. The U.S. FDA has granted Breakthrough Therapy Designation for NVL-520. Located at One Broadway, 14th Floor, Cambridge, MA 02142, Nuvalent maintains a strong financial position with an operating runway anticipated into 2027.